References
- DighieroGHamblinTJChronic lymphocytic leukaemiaLancet200837196171017102918358929
- National Cancer Institute [homepage on the Internet]Chronic lymphocytic leukemia treatment-for health professionals (PDQ) [updated January 20, 2017; cited 2016]. Available from: http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq#cit/section_1.19Accessed November 1, 2016
- RaiRStilgenbauerSEpidemiology and clinical manifestation of chronic lymphocytic leukemia [updated 2017, cited 2016]. Available from: http://www.uptodate.com/contents/clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemiaAccessed January 11, 2017
- YuEMKittaiATabbaraIAChronic lymphocytic leukemia: current conceptsAnticancer Res201535105149516526408673
- YeeKWO’BrienSMChronic lymphocytic leukemia: diagnosis and treatmentMayo Clin Proc20068181105112916901035
- HallekMChronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatmentAm J Hematol201590544646025908509
- NCCN Guidelines Version 1National Comprehensive Cancer Network (NCCN) [updated 2017, cited 2016]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdfAccessed January 11, 2017
- GaleRPRaiKRChronic lymphocytic leukemia: recent progress and future directionsJ Natl Cancer Inst19888016566
- BinetJLAuquierADighieroGA new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer19814811982067237385
- SandhuSMulliganSPOfatumumab and its role as immunotherapy in chronic lymphocytic leukemiaHaematologica2015100441141425828085
- O’SheaJJLaurenceAMcInnesIBBack to the future: oral targeted therapy for RA and other autoimmune diseasesNat Rev Rheumatol20139317318223419429
- European Medicine AgencyArzerra: EPAR-product Information [cited January 29, 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/0,01,131/WC50,00,93,091.pdfAccessed January 12, 2017
- LemerySJZhangJRothmannMDU.S. Food and drug administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumabClin Cancer Res201016174331433820601446
- National Cancer InstituteNCI Drug Dictionary – Ofatumumab [cited January 29, 2015]. Available from: http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=5,30,015Accessed January 12, 2017
- Novartis Pharmaceuticals CorporationDrugs@FDA: FDA Approved Drug Products cited 2016U.S. Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/1,25,326s062lbl.pdfAccessed January 12, 2017
- HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukenia updating the national cancer working group 1996 guidelinesBlood2008111125446545618216293
- GrossmannNBaumannMHorizon Scanning in Oncology: Ofatumumab (Arzerra) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL) cited 2016Ludwig Boltzmann Gesellschaft GmbH Available from: http://eprints.hta.lbg.ac.at/884/1/DSD_HSO_Nr.10.pdfAccessed January 12, 2017
- Novartis International AGNovartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia [cited 2015]. Available from: https://markets.ft.com/data/announce/full?dockey=1330-477844en-4OOTQKA21L3OAFDM41RMPK59DHAccessed June 20, 2017